Preventive Effects of Different Probiotic Formulations on Travelers’ Diarrhea Model in Wistar Rats
- 497 Downloads
A new animal model of travelers’ diarrhea has been developed by infecting rats orally with a strain of enterotoxigenic Escherichia coli in order to assess the efficacy of three probiotic formulations for the prevention of travelers’ diarrhea. Five groups of six rats were given daily (by oral gavage) either a placebo (negative and positive control groups), the suspension of bacterial probiotics called FF1, the yeast probiotic Saccharomyces boulardii, or a combination of both, called ProtecflorTM. After 14 days of treatment, all groups except the negative control one were infected by oral administration of E. coli. Body temperature, body weight, food and water consumption, stools consistency, behavior, and cytokines secretion were disturbed following E. coli infection. Probiotics-treated groups generally displayed less-pronounced symptoms, the combination of probiotics ProtecflorTM being the most effective.
KeywordsTravelers’ diarrhea Escherichia coli Prevention Probiotics Rat
We would like to thank Lallemand SAS France for the sponsoring this study and for the supply of probiotic samples.
- 10.Johnson-Henry KC, Riff JD, Gordanpour M, Sherman PM. Probiotics in models of gastrointestinal infections. Nutrafoods. 2005;4:29–36.Google Scholar
- 12.Martins FS, Nardi RM, Arantes RM, Rosa CA, Neves MJ, Nicoli JR. Screening of yeasts as probiotic based on capacities to colonize the gastrointestinal tract and to protect against enteropathogen challenge in mice. J Gen Appl Microbiol. 2005;51:83–92. doi: 10.2323/jgam.51.83.CrossRefPubMedGoogle Scholar
- 13.Correa NB, Peret Filho LA, Penna FJ, Lima FM, Nicoli JR. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol. 2005;39:385–389. doi: 10.1097/01.mcg.0000159217.47419.5b.CrossRefPubMedGoogle Scholar
- 19.De Simone C, Vesely R, Bianchi BS, Jirillo E. The role of probiotics in modulation of the immune system in man and in animals. Int J Immunother. 1993;9:23–28.Google Scholar
- 22.Marteau PR, De Vrese M, Cellier CJ, Schrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr. 2001;73:430–436.Google Scholar
- 28.Shanahan F. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2005;288:417–421. doi: 10.1152/ajpgi.00421.2004.CrossRefGoogle Scholar
- 33.Can M, Besirbellioglu BA, Avci IY, Beker CM, Pahsa A. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. Med Sci Monit. 2006;12:19–22.Google Scholar
- 39.Sherman PM, Johnson-Henry KC, Yeung HP, Ngo PSC, Goulet J, Tompkins TA. Probiotics reduce enterohemorrhagic Escherichia coli O157:H7- and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect Immun. 2005;73:5183–5188. doi: 10.1128/IAI.73.8.5183-5188.2005.CrossRefPubMedGoogle Scholar
- 40.Ishida-Fujii K, Sato R, Goto S, et al. Prevention of pathogenic Escherichia coli infection in mice and stimulation of macrophage activation in rats by an oral administration of probiotic Lactobacillus casei I-5. Biosci Biotechnol Biochem. 2007;71:866–873. doi: 10.1271/bbb.60464.CrossRefPubMedGoogle Scholar